(59 days)
The ATEC Lateral Interbody System is indicated for spinal fusion procedures in skeletally mature patients at one or two contiguous levels in the thoracolumbar spine.
Thoracic: T1-T2 to T11-T12, or at the thoracolumbar junction (T12-L1), following discectomy for the treatment of a symptomatic degenerative disc disease (DDD), including thoracic disc herniation (myelopathy with or without axial pain). The lateral approach is limited to levels T5-6 to T11-T12.
Lumbar: L1-L2 to L5-S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies.
The ATEC Lateral Interbody System is intended for use on patients who have had at least six months of non-operative treatment. It is intended for use with autograft and/or allograft comprised of cancellous and/or corticocancellous bone graft and supplemental fixation systems that are cleared by FDA for use in the thoracic and lumbar spine.
LIF Anti-Migration Plate (AMP) may be used with ATEC Lateral Interbody spacers to provide integrated fixation. Spacers with >20° lordosis must be used with LIF AMP integrated fixation in addition to supplemental fixation.
The ATEC Lateral Interbody System is an intervertebral body fusion system implanted from an anterolateral or lateral approach. The interbody implants consist of various lengths, widths, heights and degrees of lordosis to accommodate individual patient anatomy. These implants are manufactured PEEK (polyetheretherketone) Optima LT1 per ASTM F2026, titanium coating per ASTM F1580, tantalum per ASTM F560, titanium alloy (Ti- 6AI-4V ELI) per ASTM F136, and commercially pure titanium (CPTi Grade 2) per ASTM F67. The device includes rows of teeth on the surface of each end of the device which serve to grip the adjacent vertebrae to resist migration and expulsion of the device. Additionally, the commercially pure titanium implants are offered with a microstructure due to the layering of material that forms the porous geometry. This porous geometry extends to the superior and inferior surfaces of the device for implant fixation. All interbody implants feature an internal graft aperture for placement of graft material to promote fusion through the cage.
The ATEC Lateral Interbody System includes LIF Anti-Migration Plate (AMP) integrated fixation that may be used with all ATEC Lateral Interbody offerings. The LIF AMP integrated fixation includes fixation plates, center locking screws and bone screws manufactured from titanium alloy per ASTM F136.
This 510(k) submission includes sterile packaged AMP plates and screws. The ATEC Lateral Interbody System includes IdentiTi LIF Porous Ti Interbody, Battalion LLIF Spacer System and Transcend LIF Interbody System. Any of the three subsystems may be used with LIF AMP integrated fixation and all implants are offered sterile packaged.
This document is a 510(k) premarket notification for the ATEC Lateral Interbody System. It focuses on demonstrating substantial equivalence to previously cleared devices rather than presenting novel clinical or algorithmic performance data. Therefore, the information requested regarding acceptance criteria, study details, and AI performance is not applicable or cannot be extracted from this document.
Here's an overview of what can be extracted based on the nature of this submission:
1. A table of acceptance criteria and the reported device performance
- Not applicable. This document describes a medical device (surgical implants) and not a software algorithm that would have performance metrics like sensitivity, specificity, or accuracy. The "performance data" section refers to nonclinical testing, which is primarily about material safety and mechanical properties, not diagnostic or predictive performance.
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Not applicable. No test set for evaluating software performance is mentioned as this is not a software device. The nonclinical tests performed (e.g., Bacterial Endotoxin Test) are material and manufacturing related, not related to data samples.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not applicable. No ground truth for an algorithm or software performance is established in this document.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not applicable. No test set for algorithmic performance is discussed.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- Not applicable. This document is for a physical medical device (interbody fusion system), not an AI-powered diagnostic or assistive tool. Therefore, an MRMC study is irrelevant.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not applicable. This is not an algorithm or software-only device.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Not applicable. As no algorithmic performance is being evaluated, there is no "ground truth" in the context of diagnostic or predictive accuracy.
8. The sample size for the training set
- Not applicable. No training set for a machine learning algorithm is mentioned.
9. How the ground truth for the training set was established
- Not applicable. No training set and associated ground truth are relevant to this submission.
Summary of Information from the Document:
The document is a 510(k) premarket notification for the "ATEC Lateral Interbody System". This system is an intervertebral body fusion device made of various materials (PEEK, titanium, tantalum, titanium alloy) intended for spinal fusion procedures. The FDA determined that the device is substantially equivalent to legally marketed predicate devices based on nonclinical testing and comparison of intended use, indications for use, design, function, and technology.
The "Clinical Information" section explicitly states: "Not applicable; determination of substantial equivalence is not based on an assessment of clinical performance data."
The "PERFORMANCE DATA" section lists only one type of general nonclinical test:
- Bacterial Endotoxin Test per ANSI/AAMI ST72. The results demonstrated substantial equivalence for nonclinical testing.
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.